Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE)

Launched by RENNES UNIVERSITY HOSPITAL · Jul 26, 2021

Keywords

ClinConnect Summary

The CEPAGE trial is studying why some older adults don’t respond well to a medication called clopidogrel, which is often used to prevent heart problems. Researchers have noticed that up to 50% of people over 70 may have a resistance to this drug, meaning it might not work effectively for them. This study aims to explore how age and other health factors might affect how well clopidogrel works, particularly focusing on how the body processes the medication.

To participate, individuals should be between 50 and 100 years old and have been taking clopidogrel for at least 10 days for heart-related reasons. Participants need to give their consent for genetic testing and the collection of blood samples. Throughout the trial, participants will undergo tests to understand their body’s response to the medication better. It’s important to note that those currently taking other blood-thinning medications or with certain health conditions may not be eligible. This research could help improve treatment for older adults with heart conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Consecutive patients per 10-year age range, (20 patients per age range from 50 to 100 years included) :
• • in consultation or hospitalization in one of the participating centres,
• • treatment with clopidogrel 75 mg/d for at least 10 days for primary or secondary prevention of cardiovascular events.
• • who have received the information and have not expressed their opposition to participate in the study and who have given their written consent for the performance of genetic examinations and the realization of a biocollection
• • affiliated to French social security system
• Exclusion criteria :
• • treatment with another antithrombotic agent,
• • myeloproliferative syndrome,
• • platelet count \< 100 G/L,
• • acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,
• • under dialysis,
• • no participation in another clinical study,
• • deprived of liberty